Rapamycin Intervention

Rapamycin is a drug initially approved by the FDA in 1999, primarily to prevent organ transplant rejection, particularly in kidney transplant patients. It has also been used in treating certain types of cancers and rare disorders caused by the hyperactivation of mTOR, the protein inhibited by Rapamycin. Additionally, it has applications in preventing cell regrowth over cardiac stents 1.

Rapamycin has been identified as having significant potential in the field of age-related diseases and longevity. It can reverse functional declines in the immune system and heart function among old mice treated for four to twelve weeks 1. Moreover, Rapamycin is effective in reducing age-related sterile inflammation, and anecdotal evidence suggests it can improve conditions like adhesive capsulitis (frozen shoulder) 2.

However, continuous usage of Rapamycin, especially in high doses, is associated with side effects, particularly when used as an immunosuppressant in organ transplant patients. This has led to considerations of cycling on and off the drug rather than continuous use, to potentially minimize side effects while still garnering its benefits 3.